# Karl Landsteiner Society

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/karl-landsteiner-society/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 66 |
| Citations | 97,051 |
| City | St. Pölten |
| Country | AT |
| Description | Karl Landsteiner Society is a research organisation in St. Pölten, AT. OpenAlex records 2,844 works and 97,051 citations for it. 593 researchers list it as their most recent affiliation. |
| Homepage | https://karl-landsteiner.at |
| OpenAlex ID | https://openalex.org/I4210161345 |
| Region | Lower Austria |
| Researchers | 593 |
| ROR ID | https://ror.org/05r0e4p82 |
| Type | other |
| Works | 2,844 |

## University papers

Showing 12 of 13.

- [First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung/)
- [Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer](https://scholariq.org/papers/capmatinib-in-i-met-i-exon-14-mutated-or-i-met-i-amplified-non-small-cell-lung/)
- [Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-i-alk-i-positive-non-small-cell-lung-cancer/)
- [Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer](https://scholariq.org/papers/perioperative-durvalumab-for-resectable-non-small-cell-lung-cancer/)
- [Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study](https://scholariq.org/papers/pembrolizumab-plus-pemetrexed-and-platinum-in-nonsquamous-non-small-cell-lung/)
- [Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial](https://scholariq.org/papers/brigatinib-in-patients-with-crizotinib-refractory-anaplastic-lymphoma-kinase/)
- [Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging](https://scholariq.org/papers/slow-expansion-of-multiple-sclerosis-iron-rim-lesions-pathology-and-7-t-magnetic/)
- [European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism](https://scholariq.org/papers/european-position-paper-on-the-management-of-patients-with-patent-foramen-ovale/)
- [Alectinib in Resected <i>ALK</i> -Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/alectinib-in-resected-i-alk-i-positive-non-small-cell-lung-cancer/)
- [Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-alk-inhibitor-naive-advanced-alk-positive-nsclc/)
- [Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-advanced-alk-inhibitor-naive-alk-positive-non/)
- [Human CLP1 Mutations Alter tRNA Biogenesis, Affecting Both Peripheral and Central Nervous System Function](https://scholariq.org/papers/human-clp1-mutations-alter-trna-biogenesis-affecting-both-peripheral-and-central/)

## University top topics

Showing 8 of 25.

- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Urinary and Genital Oncology Studies](https://scholariq.org/topics/urinary-and-genital-oncology-studies/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Epilepsy research and treatment](https://scholariq.org/topics/epilepsy-research-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Inflammatory Biomarkers in Disease Prognosis](https://scholariq.org/topics/inflammatory-biomarkers-in-disease-prognosis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.